{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:50:34Z","timestamp":1791946234713,"version":"4.3.4"},"reference-count":71,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002561","name":"ALS Hope Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002561","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS104022"],"award-info":[{"award-number":["R01 NS104022"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35 GM131839"],"award-info":[{"award-number":["R35 GM131839"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10 OD020012"],"award-info":[{"award-number":["S10 OD020012"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001341","name":"Richard and Susan Smith Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000971","name":"ALS Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000971","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013013","name":"Target ALS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01 NS111990"],"award-info":[{"award-number":["R01 NS111990"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["DP2 OD027719-01"],"award-info":[{"award-number":["DP2 OD027719-01"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS131756"],"award-info":[{"award-number":["NS131756"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NR020231"],"award-info":[{"award-number":["NR020231"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["U24NS113844"],"award-info":[{"award-number":["U24NS113844"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001447","name":"Rita Allen Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ymthe.2025.05.010","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T13:14:26Z","timestamp":1746796466000},"page":"3917-3938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS mice"],"prefix":"10.1016","volume":"33","author":[{"given":"Alexandra","family":"Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris Valeria","family":"Rivera Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian","family":"Belgrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif O.","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Wightman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kit","family":"Mocarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimas","family":"Echeverria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley L.","family":"Harkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Summers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Bramato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"McHugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Furgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Monopoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno M.D.C.","family":"Godinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Hassler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Greer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Henninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Robert H.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6928-8071","authenticated-orcid":false,"given":"Anastasia","family":"Khvorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.05.010_bib1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/B978-0-12-802973-2.00013-6","article-title":"The epidemiology of amyotrophic lateral sclerosis","volume":"138","author":"Talbott","year":"2016","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.ymthe.2025.05.010_bib2","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/ene.14393","article-title":"Amyotrophic lateral sclerosis: a clinical review","volume":"27","author":"Masrori","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ymthe.2025.05.010_bib3","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.neuron.2021.12.019","article-title":"Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis","volume":"110","author":"Zhang","year":"2022","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2025.05.010_bib4","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41588-021-00973-1","article-title":"Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology","volume":"53","author":"van Rheenen","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2025.05.010_bib5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","article-title":"Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS","volume":"72","author":"DeJesus-Hernandez","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2025.05.010_bib6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","article-title":"A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD","volume":"72","author":"Renton","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2025.05.010_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/362059a0","article-title":"Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis","volume":"362","author":"Rosen","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.05.010_bib8","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1126\/science.1166066","article-title":"Mutations in the FUS\/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis","volume":"323","author":"Kwiatkowski","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.05.010_bib9","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.1165942","article-title":"Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6","volume":"323","author":"Vance","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.05.010_bib10","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1126\/science.1154584","article-title":"TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis","volume":"319","author":"Sreedharan","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.05.010_bib11","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41576-023-00592-y","article-title":"Amyotrophic lateral sclerosis: translating genetic discoveries into therapies","volume":"24","author":"Ak\u00e7imen","year":"2023","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2025.05.010_bib12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3389\/fneur.2019.00527","article-title":"Structural Properties and Interaction Partners of Familial ALS-Associated SOD1 Mutants","volume":"10","author":"Huai","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymthe.2025.05.010_bib13","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2174\/1568026611212220010","article-title":"SOD1 aggregation and ALS: role of metallation states and disulfide status","volume":"12","author":"Sheng","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ymthe.2025.05.010_bib14","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1007\/s00018-013-1385-2","article-title":"Extracellular wildtype and mutant SOD1 induces ER-Golgi pathology characteristic of amyotrophic lateral sclerosis in neuronal cells","volume":"70","author":"Sundaramoorthy","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ymthe.2025.05.010_bib15","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1471-4159.2007.05053.x","article-title":"Superoxide dismutase 1 mutants related to amyotrophic lateral sclerosis induce endoplasmic stress in neuro2a cells","volume":"104","author":"Oh","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ymthe.2025.05.010_bib16","doi-asserted-by":"crossref","first-page":"15587","DOI":"10.1523\/JNEUROSCI.2037-14.2014","article-title":"Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex","volume":"34","author":"Thomsen","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ymthe.2025.05.010_bib17","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1172\/JCI99081","article-title":"Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models","volume":"128","author":"McCampbell","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.05.010_bib18","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40265-023-01904-6","article-title":"Tofersen: First Approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2025.05.010_bib19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1089\/nat.2023.0027","article-title":"From Failure to Meet the Clinical Endpoint to U.S. Food and Drug Administration Approval: 15th Antisense Oligonucleotide Therapy Approved Qalsody (Tofersen) for Treatment of SOD1 Mutated Amyotrophic Lateral Sclerosis","volume":"33","author":"van Roon-Mom","year":"2023","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2025.05.010_bib20","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/d41573-021-00181-w","article-title":"ALS antisense drug falters in phase III","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.05.010_bib21","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.05.010_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102495","article-title":"Effects of tofersen treatment in patients with SOD1-ALS in a \u201creal-world\u201d setting a 12-month multicenter cohort study from the German early access program","volume":"69","author":"Wiesenfarth","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.ymthe.2025.05.010_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102147","article-title":"Intrathecal administration of a novel siRNA modality extends survival and improves motor function in the SOD1(G93A) ALS mouse model","volume":"35","author":"Duan","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.05.010_bib24","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","article-title":"Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates","volume":"40","author":"Brown","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.05.010_bib25","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41587-019-0205-0","article-title":"A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system","volume":"37","author":"Alterman","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.05.010_bib26","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2219523120","article-title":"Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection","volume":"120","author":"Hariharan","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.05.010_bib27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.omtn.2022.06.005","article-title":"PK-modifying anchors significantly alter clearance kinetics, tissue distribution, and efficacy of therapeutics siRNAs","volume":"29","author":"Godinho","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.05.010_bib28","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.05.010_bib29","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.05.010_bib30","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1093\/nar\/gky037","article-title":"Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo","volume":"46","author":"Hassler","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.05.010_bib31","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1089\/nat.2023.0068","article-title":"Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation","volume":"34","author":"Belgrad","year":"2024","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2025.05.010_bib32","doi-asserted-by":"crossref","first-page":"10905","DOI":"10.1093\/nar\/gky745","article-title":"Functional features defining the efficacy of cholesterol-conjugated, self-deliverable, chemically modified siRNAs","volume":"46","author":"Shmushkovich","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.05.010_bib33","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1093\/nar\/gkaa595","article-title":"The chemical structure and phosphorothioate content of hydrophobically modified siRNAs impact extrahepatic distribution and efficacy","volume":"48","author":"Biscans","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.05.010_bib34","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.tips.2023.08.008","article-title":"ASO drug Qalsody (tofersen) targets amyotrophic lateral sclerosis","volume":"44","author":"Jin","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ymthe.2025.05.010_bib35","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1096\/fj.13-228668","article-title":"Single modification at position 14 of siRNA strand abolishes its gene-silencing activity by decreasing both RISC loading and target degradation","volume":"27","author":"Zheng","year":"2013","journal-title":"Faseb j"},{"key":"10.1016\/j.ymthe.2025.05.010_bib36","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3233\/JND-140068","article-title":"Characterization of the Contribution of Genetic Background and Gender to Disease Progression in the SOD1 G93A Mouse Model of Amyotrophic Lateral Sclerosis: A Meta-Analysis","volume":"2","author":"Pfohl","year":"2015","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.05.010_bib37","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","article-title":"Therapeutic siRNA: State-of-the-Art and Future Perspectives","volume":"36","author":"Friedrich","year":"2022","journal-title":"BioDrugs."},{"key":"10.1016\/j.ymthe.2025.05.010_bib38","article-title":"Extended Nucleic Acid (exNA): A Novel, Biologically Compatible Backbone that Significantly Enhances Oligonucleotide Efficacy in vivo","author":"Yamada","year":"2023","journal-title":"bioRxiv."},{"key":"10.1016\/j.ymthe.2025.05.010_bib39","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bbagrm.2007.11.004","article-title":"RNA recognition by 3'-to-5' exonucleases: the substrate perspective","volume":"1779","author":"Ibrahim","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymthe.2025.05.010_bib40","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1124\/dmd.121.000381","article-title":"Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved N-Acetylgalactosamine-Conjugated RNA Interference Therapeutic","volume":"49","author":"Li","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ymthe.2025.05.010_bib41","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1093\/nar\/gkaa299","article-title":"Phosphorothioate modified oligonucleotide-protein interactions","volume":"48","author":"Crooke","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.05.010_bib42","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/nat.2018.0773","article-title":"Evaluating the Impact of Variable Phosphorothioate Content in Tricyclo-DNA Antisense Oligonucleotides in a Duchenne Muscular Dystrophy Mouse Model","volume":"29","author":"Echevarr\u00eda","year":"2019","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2025.05.010_bib43","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s13311-022-01247-2","article-title":"Antisense Oligonucleotides for the Study and Treatment of ALS","volume":"19","author":"Boros","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ymthe.2025.05.010_bib44","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/path.2993","article-title":"Silencing disease genes in the laboratory and the clinic","volume":"226","author":"Watts","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.ymthe.2025.05.010_bib45","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cell.2015.06.029","article-title":"Single-Molecule Imaging Reveals that Argonaute Reshapes the Binding Properties of Its Nucleic Acid Guides","volume":"162","author":"Salomon","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.05.010_bib46","doi-asserted-by":"crossref","DOI":"10.52965\/001c.24934","article-title":"The Antisense Oligonucleotide Nusinersen for Treatment of Spinal Muscular Atrophy","volume":"13","author":"Edinoff","year":"2021","journal-title":"Orthop. Rev."},{"key":"10.1016\/j.ymthe.2025.05.010_bib47","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.05.010_bib48","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1093\/nar\/gkaa126","article-title":"Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model","volume":"48","author":"Sheng","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.05.010_bib49","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","article-title":"Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2025.05.010_bib50","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.05.010_bib51","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.152203","article-title":"Comparative route of administration studies using therapeutic siRNAs show widespread gene modulation in Dorset sheep","volume":"6","author":"Ferguson","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.05.010_bib52","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.05.010_bib53","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00018-023-04956-9","article-title":"Selective removal of misfolded SOD1 delays disease onset in a mouse model of amyotrophic lateral sclerosis","volume":"80","author":"Guan","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ymthe.2025.05.010_bib54","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.drudis.2007.10.011","article-title":"Strategic approaches to developing drug treatments for ALS","volume":"13","author":"Vincent","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ymthe.2025.05.010_bib55","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/1087057110397888","article-title":"Chemical library screening identifies a small molecule that downregulates SOD1 transcription for drugs to treat amyotrophic lateral sclerosis","volume":"16","author":"Murakami","year":"2011","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.ymthe.2025.05.010_bib56","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1073\/pnas.0408277102","article-title":"Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation","volume":"102","author":"Ray","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.05.010_bib57","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1038\/s41467-018-05127-2","article-title":"A small-molecule inhibitor of SOD1-Derlin-1 interaction ameliorates pathology in an ALS mouse model","volume":"9","author":"Tsuburaya","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.05.010_bib58","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/ana.24950","article-title":"Pyrimethamine significantly lowers cerebrospinal fluid Cu\/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations","volume":"81","author":"Lange","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2025.05.010_bib59","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41392-023-01486-5","article-title":"Role of neuroinflammation in neurodegeneration development","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2025.05.010_bib60","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/alz.13703","article-title":"Silencing Apoe with divalent-siRNAs improves amyloid burden and activates immune response pathways in Alzheimer's disease","volume":"20","author":"Ferguson","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.ymthe.2025.05.010_bib61","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/WCO.0000000000000984","article-title":"Therapeutic strategies for C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia","volume":"34","author":"Hautbergue","year":"2021","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.ymthe.2025.05.010_bib62","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.001","article-title":"Targeting RNA-Mediated Toxicity in C9orf72 ALS and\/or FTD by RNAi-Based Gene Therapy","volume":"16","author":"Martier","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.05.010_bib63","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41591-021-01557-6","article-title":"Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide","volume":"28","author":"Tran","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.05.010_bib64","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-021-01615-z","article-title":"Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis","volume":"28","author":"Korobeynikov","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.05.010_bib65","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s13311-022-01260-5","article-title":"Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS\/FTD","volume":"19","author":"Hayes","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ymthe.2025.05.010_bib66","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi2245","article-title":"Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier","volume":"16","author":"Barker","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2025.05.010_bib67","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ymthe.2025.05.010_bib68","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2025.05.010_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101122","article-title":"Awake intracerebroventricular delivery and safety assessment of oligonucleotides in a large animal model","volume":"31","author":"Benatti","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.05.010_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102359","article-title":"Preventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of Ca2+ and Mg2+ in the formulation","volume":"35","author":"Miller","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.05.010_bib71","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s40478-021-01220-8","article-title":"Mouse closed head traumatic brain injury replicates the histological tau pathology pattern of human disease: characterization of a novel model and systematic review of the literature","volume":"9","author":"Kahriman","year":"2021","journal-title":"Acta Neuropathol. Commun."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625003806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625003806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:28:10Z","timestamp":1783020490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625003806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":71,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1525001625003806"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.05.010","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.06.20.599943","asserted-by":"object"}]},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS mice","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}